Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

Rekrutierend

NCT-Nummer:
NCT00457587

Studienbeginn:
September 2005

Letztes Update:
24.04.2024

Wirkstoff:
-

Indikation (Clinical Trials):
Carcinoma, Adrenocortical Carcinoma, Cushing Syndrome

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
University of Wuerzburg

Collaborator:
Deutsche Krebshilfe e.V., Bonn (Germany)

Studienleiter

Martin Fassnacht, MD
Principal Investigator
University of Wuerzburg

Kontakt

Martin Fassnacht, MD
Kontakt:
Phone: 49-931-201-36507
E-Mail: fassnacht_m@medizin.uni-wuerzburg.de» Kontaktdaten anzeigen

Laura Landwehr, PhD
Kontakt:
E-Mail: Landwehr_l@ukw.de» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

Dept. of Medicine I, University of Wuerzburg
97080 Wuerzburg
(Bayern)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Martin Fassnacht, MD
Phone: 49-931-201-36507
E-Mail: fassnacht_m@medizin.uni-wuerzburg.de

Silviu Sbiera, PhD
E-Mail: sbiera_s@medizin.uni-wuerzburg.de» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis.

Surgical resection of the tumor is the treatment of choice. However, even after complete

resection more than 80 % of patients will experience recurrence of disease. Therefore, new

treatment options are urgently needed. This pre-clinical study try to lay the foundations for

a successful immunotherapy in patients with ACC.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- patients with histological proven adrenocortical carcinoma

- healthy persons as control group

- Life expectancy > 6 months

Exclusion Criteria:

- autoimmune diseases

- severe clinical condition

Studien-Rationale

Primary outcome:

1. To find reasonable antigens for a vaccination therapy in ACC (Time Frame - day of blood sampling)

2. To investigate the role of tumor-induced suppression in ACC (Time Frame - NA, in vitro study)

Quelle: ClinicalTrials.gov